Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...
Revenue and profits are still important measures, but Lemonade's favored top-line metric is in-force premiums (IFP), or the average of current ... where it's been holding for the past three quarters ...
Nu Skin Enterprises, Inc. NUS is likely to register a decline in top and bottom lines when it reports third-quarter 2024 earnings on Nov. 7. The Zacks Consensus Estimate for revenues is pegged at $444 ...
YTHDF1 binds to m6A modification sites on SFTSV, decreasing the stability of SFTSV RNA and reducing translation efficiency of SFTSV proteins. SFTSV protein NSs promotes YTHDF1 lactylation to inhibit ...